Peggy J. Berry, MBA, RAC, is the President & CEO at Synergy Consulting where she provides consulting services to companies in all aspects of drug development. She also provides group and one-on-one training in drug development, regulatory affairs and project management topics. Prior to founding Synergy Consulting in 2015, she was Vice President of Regulatory Affairs at Insmed where she was responsible for the development and implementation of global regulatory strategies and the management and oversight of the regulatory affairs department. Prior to Insmed, she was Vice President of Regulatory Affairs and Quality at Amarin. In addition, Ms. Berry consults for a number of companies in the regulatory and quality area, conducts a number of training courses, and is active in the Regulatory Affairs Professionals Society. She is the editor of the 2010 book “Choosing the Right Regulatory Career” (RAPS, MD) and author of the 2011 book “Communication & Negotiation” (RAPS, MD).

Regulatory Affairs

Prof David Naor is a professor of immunology in the Hebrew University, faculty of Medicine and was the head of Milton Winograd Chair of Cancer Studies. He received his Ph.D from the Hebrew University. He served as visiting professor in leading universities (e.g., UCLA, Harvard). He published 152 articles, including in leading journals like Nature, PNAS, J Clin Invest, J immunol, J Exp Med etc. He was invited to speak on CD44 at 8 plenary sessions of international conferences. He has been a member in editorial boards of several international scientific journals and he is an associate editor of Frontiers in Immunology. He is on the scientific board of International Congress on Autoimmunity. He received awards from Johnson & Johnson "In recognition of outstanding research towards the advances of science and technology in health care” and from the Hebrew University for his “outstanding achievements in research and teaching”.

Prof David Naor current research has been focused on the role of CD44 and other hyaluronan-binding molecules (e.g., RHAMM) in autoimmune and cancer diseases. This CD44 research yielded 34 articles, which were cited thousands of times.

Christina Leung completed two Bachelor degrees in England (the Management Sciences degree and the Pharmacy degree). Following the registration as a pharmacist in England, she worked in a number of teaching hospitals in London. After the completion of junior pharmacist training, Ms Leung spent 12 years as Women’s and Children’s Pharmacist, mainly specialising in Paediatric ICU, Paediatric Liver, Obstetrics & Gynaecology. She published a number of articles including two articles relating to drugs use in paediatric liver diseases. Ms Leung is also a registered pharmacist in HK and she is currently working as the Senior Pharmacist (Clincial Service) at HKU-SZH. She is currently the Honorary Lecturer at the University of Hong Kong.

Ms Leung has special intertess in clincial pharmacy system of different aspects and its impact in the quality of patient care. In addition, Ms Leung has great interests in medication safety, risk management, antimicrobial stewardship, quality management, training and education, and continuous professional development.

Gopal Natesan has completed his Doctoral degree (PhD) in Pharmaceutical Chemistry from Hamdard University (Jamia Hamdard) New Delhi, India in 2000 and currently serving as Professor of Medicinal Chemistry & Deputy Dean of Research & Innovation in Faculty of Pharmacy, MAHSA University, Kuala Lumpur, Malaysia. His research focuses on the synthesis of newer small chemical entities, quinazolinones heterocyclic pharmacophore and their preliminary screening in both in-vivo and in- vitro models mainly focusing on pain & inflammation and also for newer microbial agents. He has published >40 articles in indexed journals and presented >80 papers in conferences and received number of honors, recently received “Young Scientist Award” in 2013 and “Edward Kennedy Memorial Award” for his high standards of research excellence in Science and Technology. He was invited speaker at international scientific meetings and conferences and serves as reviewer for several scientific international journals and also as Editorial/Advisory board of various journals.

Pharmaceutical Chemistry

After completion of his postdoctoral training at University of Texas MD Anderson Cancer Center, Prof. Gautam Sethi joined Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore in 2008 as an Assistant Professor and was promoted to Associate Professor in 2015. The focus of his research over the past few years has been to elucidate the mechanism(s) of activation of oncogenic transcription factors such as NF KB/STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. From traditional Chinese and Indian medicinal plants, his group has identified numerous small molecules that can suppress various pro-tumorigenic signaling cascades involved in cancer initiation and promotion. The novel findings of his research work have so far resulted in more than one fifty scientific publications in high impact factor peer reviewed journals and several international awards. He currently serves as an Academic Editor for prestigious PLOS One journal and ad-hoc reviewer for several other international journals.

Pharmacology

Dr Yahaya Hassan is a Professor of Clinical Pharmacy, Pharmacy Practice Department at Faculty of Pharmacy,Universiti Teknologi MARA (UiTM), Malaysia. He also serve as a consultant for Malaysian Qualifying Agency (MQA) Ministry of Higher Education of Malaysia and MQA panel member for Board of Pharmacy of Malaysia. He also serve as a committee member of Clinical Pharmacy Specialist development program for Pharmacy Division,Ministry of Health of Malaysia. Prof Yahaya obtained his B.Pharm from Universiti Sains Malaysia and Pharm.D. from University of Minnesota, USA. He has been lecturing at the faculty of Pharmacy for 32 years covering courses in clinical pharmacy, pharmacokinetics, advanced pharmacotherapeutics and pharmacy practice. He has successfully supervised over 20 research postgraduate students at the master’s and Ph.D levels, more than 200 master’s by coursework and published over 110 research papers in international journals and another 40 in regional and local journals.

His current research interest focus on clinical pharmacy, pharmacoepidemiology and pharmaceutical outcome study.

Dr Aref Alabed, A competent manager with extensive years of experience in leading arnmedical facility. He implements policies and procedures, focusing on the development ofrnthe organization by fulfilling the mission, vision and goals. The objectives are his top priorities. Dr. Aref is a Dentist , holding an MBA with Merit from Northampton university in UK, he is the Founder & CEO for the International Medical Training Academy in London, and an international relations Consultant for the Largest Chain of pharmacies in Jordan with more than 100 pharmacies today (Dawacom). He was the Marketing director and built the Marketing department from scratch.

Healthcare, Medical services, Training.

Prof. Sinerik Ayrapetyan has received his PhD in Cell Biophysics in the Institute of Physiology of Ukraine Academy of Sciences, Kiev during the period of 1966-1970. Currently, he is the coordinator of UNESCO Chair at Life Sciences International Postgraduate Educational Center, Yerevan, Armenia. He has successfully completed his Administrative responsibilities as the president of Life Sciences International Postgraduate Educational Center. His research has included the study of metabolic regulation of cell function in norm and pathology. He is serving as an editorial member of several reputed journals like “Electromagnetic Biology and Medicine”, “ISRN Biophysics”, “European Journal of Biophysics”, “Advances in Life Sciences", “Bioavailability and Bioequivalence”, “Applied Pharmacy”, “BBA General Subjects”, “International Dental and Medical Research", “International Journal of Basic and Applied Sciences” & expert Reviewer for journals like “Brain research”, “Radiobiology”, “Bioelectromagnetics”, “Journal of Alzheimer’s diseases”, “Life Sciences” etc. He has authored 7 international books and 115 research articles.

Current research interest is “Intracellular Signaling System in Norm and Pathology”

Hari Shanker Sharma, Director of Research (International Experimental Central Nervous System Injury & Repair, IECNSIR), University Hospital, Uppsala University is Professor of Neurobiology (MRC), Docent in Neuroanatomy (UU) and is currently affiliated with Department of Surgical Sciences, Division of Anesthesiology and Intensive Care Medicine, Uppsala University, Sweden. Hari Sharma was born on January 15, 1955 in an Industrialist town Dalmianagar (Bihar), India. He did his Bachelor of Science with Honors from the prestigious L. S. College Muzaffarpur in 1973 and secured 1st position in his batch. He obtained his Master Degree from Bihar University with special expertise in Cell Biology in 1976 and awarded Gold Medal of Bihar University for securing 1st potion in the 1st Class. Hari Sharma joined the group of Professor Prasanta Kumar Dey, a neurophysiologist by training in the Department of Physiology, Institute of Medical; Sciences, Banaras Hindu University, Varanasi in 1977 to obtain Doctor of Philosophy Degree (D.Phil.) in Neurosciences and was awarded Ph.D. in 1982 on “Blood-Brain Barrier in Stress.” Hari Sharma after carrying out a series of Government of India funded Research Projects on the BBB and brain dysfunction (1982–1987), joined the lab of Neuropathology at Uppsala University with Professor Yngve Olsson in 1988 to investigate passage of tracer transport across the BBB caused by stress or traumatic insults to the Brain and Spinal cord at light and electron microscopy. Dr. Sharma awarded the prestigious Alexander von Humboldt Foundation Fellowship of German Government (1989–1991) to work on hyperthermia induced BBB dysfunction at the ultrastructural level in the laboratory of Professor Jorge Cervós-Navarro (a living “Legend in Neuropathology in Europe”). Dr. Sharma joined again Uppsala University and established a network of collaboration on “Experimental CNS Injury Research Group” as a lead investigator with eminent collaborators in various parts of Europe, USA, and Australia (1991–). On his work on hyperthermia Dr. Sharma received the prestigious Neuroanatomy award “Rönnows Research prize” of Uppsala University for “best neuroanatomical research of the year 1996” followed by the Award of the Degree of Doctor of Medical Sciences of Uppsala University in Neuroanatomy in 1999 and selected for the Best Thesis Award of the Medical faculty, “The Hwassers Prize” of 1999. On his meticulous works on the Blood Brain barrier and Brain edema (2000–2003) Dr. Sharma earned the prestigious title of “Docent in Neuroanatomy” of Medical Faculty, Uppsala University in April 2004. Currently his main research interest is Neuroprotection and Neuroregeneration, in relation to the Blood-brain barrier in stress, trauma, and drugs of abuse in health and disease. Dr. Sharma on his research on brain pathology and neuroprotection in different models received the prestigious awards from The Laerdal Foundation of Acute Medicine, Stavanger, Norway, in 2005 followed by Distinguished International Scientists Collaboration Award by National Institute on Drug Abuse (NIDA), Baltimore, MD (2006–2008). His recent work on 5-HT3 receptor mediated neuroprotection in morphine withdrawal induced neurotoxicity won the coveted prize of Best Investigator Award 2008 and Best Scientific Presentation by European Federation of the International Association for Study of Pain (ISAP), and Awarded during their VI Annual Meeting in Lisbon, September 9–12, 2008. His recent research is aimed to find out the role of nanoparticles in Neurodegeneration and Neuroprotection using various treatment strategies that is supported by European Aerospace Research and Development (EOARD), London, UK and US Air Force Research Laboratory, Wright Patterson Air Force Base, Dayton, Oh, USA. On his works on Blood–brain barrier in hypertension and diabetes together with Romanian colleagues, University of Medicine and Pharmacy “Iuliu Hatieganu,” Cluj-Napoca, Romania awarded Dr. Sharma with Honorary Doctorate of Medical Sciences in 2009. Dr. Sharma’s work over 30 years on the blood-brain barrier and brain edema won him the US Neurosurgeon Dr. Anthony Marmarou Award (2011) by the International Brain Edema Society at their 15th Congress in Tokyo, Japan, November 20–24, 2011. His works on Nanoneuroscience and development of nanomedicine to treat the CNS injuries has won accolades at various Government and International Scotties or Organization across the World. Accordingly Dr Sharma was decorated with the most prestigious “Hind Rattan Award 2012” (Jewel of India) on the eve of Republic Day of India 25th January 2012 and Mahatma Gandhi Pravasi Gold Medal on October 12, 2012 in House of Lords, London, UK. Based on his outstanding contribution in Nanoneuropharmacology and nanodrug delivery to treat central nervous system (CNS) diseases including Neurodegenerative diseases such as Alzheimer’s and Parkinson’s Hari Sharma bestowed with Prestigious Gujarat Govt. International Visionary Award 2012 in a glittering function in Ahmedabad, Gujarat on Nov 23, 2012. His further research on co-morbidity factors e.g., hypertension or diabetes may alter pathophysiology of brain injuries and require higher drug dose or nanodrug delivery of neuroprotective agents to minimize brain dysfunction is recognized by Govt. of India by presenting him one of the coveted “Bharat Jyoti Award 2013” (Glory of India) by His Excellency Governor Balmiki Prasad Singh in Hotel Le Meridien, New Delhi on Jan 12, 2013. Dr Sharma also received the highest Award of the Govt. of India “Navrattan Award 2013” (Nine Jewels of India) on the eve of 64th Republic Day of India (25th January 2013) by His Excellency Governor Bhishma Narain Singh, in Ashok Hotel, New Delhi. Hari Sharma is Founding President of the Global College of Neuroprotection & Neuroregeneration (2004-); Elected President of International Association of Neurorestoratology (IANR) (2014-); and selected Senior Expert of Asia-Pacific CEO Association, Worldwide (APCEO) (2012-) for his contribution to uplift scientific research in many countries Globally that may have better economic and social benefit for the mankind. Hari Sharma awarded coveted National Award “Sword of Honor” 2015 by Govt. of India on the eve of 66th Republic Day of India 25th January 2015 in New Delhi Eros Hotel International during the 34th Non-resident Indian (NRI) conclave by Speaker of Lok Sabha (Indian Parliament) the Hon’ble Mrs Meira Kumar of Indian national Congress (INC) Party for the continued extraordinary achievement in nanomedicine for public health awareness and possible therapeutic measures. Based on his expertise in Nanoneuroscience, Hari Sharma was also invited to organize and chair Nanosymposium in Society for Neuroscience meetings in Chicago (2009), San Diego (2010), Washington DC (2011), New Orleans (2012), San Diego (2013) and Washington DC (2014, Nov 15-19, 2014); Chair Neurobiology Symposium 14th Int. Amino Acid & Peptide, Vienna, Austria; Keynote speaker & Chair Nanotechnology-2015, Frankfurt, Germany. Hari Sharma is also the recipient of Prestigious US TechConnect Global Innovation Award 2013 at the National Innovation Summit & Innovation Showcase, Washington DC May 12-16, 2013 on his work on Nanowired cerebrolysin in Neuropathic Pain. Hari Sharma Served as one of the Poster Judges in 2014 Annual Meeting of American Association fo Advancement of Science (AAAS) Held in Chicago, IL, USA Feb 13-17, 2014. Hari Sharma has published over 400 research papers, 85 reviews, 14 monographs, and 80 international book chapters and edited 18 book volumes. He served as Guest Editor of Curr. Pharm. Desig. (2005, 2007, 2010–); J Neural. Transmiss. (2006, 2011–) and is the founding Editor-in-Chief of Int. J. Neuroprotec. Neuroregen. (2004–), UK and the European Editor of Central Nervous system-Neurological Disorders Drug Target (2013-). Dr. Sharma is on board of various International Journals including CNS and Neurological Disorders-Drug Targets, USA (2010), Journal of Neurodegeneration and Regeneration, USA (2009–); Austin Journal of Nanomedicine & Nanotechnology (2014-); and is associate editor of Journal of Nanoscience and Nanotechnology (Nanoneuroscience 2006–), USA, Review Editor—Frontiers in Neuroengineering (2007–), Frontiers in Neurorestoratology, and Associate Editor of Frontiers in Aging Neuroscience (2008–), Frontiers of Fractal Physiology (2010–), Switzerland, Journal of Neurorestoratology, Dove Medical press, London, UK (2012–), WebMD Central, Neurology Faculty, Advisory Board Member (2010–), World Journal of Pharmacology (2011–), Journal of Physical Medicine and Rehabilitation, USA (2012–). Dr. Sharma served as volume editor of several progress in Brain research series (Volumes 104, 115, 162 and 180), International review of Neurobiology (Volume 82 and 102) and other Springer Volumes on Spinal cord injury (1988) and Handbook of Neurochemistry (2009) apart from stand alone books (Elsevier, Springer and Academic Press since 1994). Dr. Hari Sharma is invited to join several National Academies of repute including New York Academy fo Science, USA (since 1994–); International Academy of Stress, New York (2003–), Swedish Academy of Pharmaceutical Sciences (2010–). Dr. Sharma has served as an expert evaluator and advisor to various Boards, Councils and Institutions for their Research Grants including Wellcome Trust, London, UK (2011–); Catalan Agency for Health Information and Quality, TV3 (2010–), European Commission Projects (2002–), European Nanomed Council (2009–), Ministry of Health Science Foundation; Medical research Council and University Commission of Grants in various countries in Europe, USA, UK, Canada, Hong Kong, Singapore and in Australia. Some of the notable organizations include: Australia and New Zealand Health Council (2000–); University Commission of Grants, Hong Kong (2002–), Singapore Medical Council, Singapore (2003–); UK Charity Organization “Research on Ageing: Help the Aged” (2003–); Euro Nanomed (2010–). Dr. Sharma is designated as ambassador of the City of Uppsala 2007, by Uppsala County administration and Uppsala Tourism for promoting Uppsala, Sweden as International Research Collaboration/Meetings and Conference Destination. Dr. Hari Sharma is married to Aruna Sharma (nee Bajpai) since 23rd April 1979 and has two sons. His political affiliations belong to Swedish Social Democrat Party (Socialdemokraterna, Sverige) where he is associated with the development of Education and Research matters in Sweden actively.

Nanoscience Nanoneuroscience

will be updated soon..

Cell stress proteins, nuclear / hormone receptors, transcription factors and microRNAs in high salt, high permeability, high sugar, oxidative stress, environmental toxins and xenobiotics stress and other cellular stress response as well as diabetes and complications of diabetes, high blood pressure, the role and mechanism of cancer and other serious diseases in humans.

will be updated soon..

Preformulation, HPLC assay development, Invitro drug release, Solid dosage formulations

Dr. Jayachandra Babu Ramapuram is an Associate Professor at the Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University. He received his Bachelor’s degree in Pharmacy from the University of Madras and Masters and PhD degrees in Pharmaceutics from Indian Institute of Technology, Varanasi, India.He is currently major/co-major advisor to 6 Ph.D. students and has successfully graduated 5 students under his guidance. His laboratory is funded by few startup and mid-size pharmaceutical companies. He has authored and co-authored 50 research papers and 4 book chapters, and presented his research work in 60 poster and oral presentations in the several national and international conferences. He has served as a chair and co-chair of scientific sessions at the Annual National Meetings of American Association of Pharmaceutical Scientists and Society of Toxicology. He serves as an editorial board member for two journals and as a peer reviewer for more than 25 journals.

His research interests include formulation development of nanoparticle based formulations for topical and oral delivery, solubility improvement of insoluble drugs, percutaneous penetration enhancement techniques, transdermal drug delivery systems.

Amr Amin has completed his PhD at University of Illinois at Chicago, and received a post-doctoral training in the field of molecular genetics at the University of Pennsylvania School of Medicine. He started his academic career at UAE University where he serves now as a Full Professor of Cell Biology. Amr’s research focuses on ways to control cancer, particularly liver cancer. He published many research articles and reviews and serves as reviewer and as an editorial member of many specialized peer-reviewed journals. He is also a member of many specialized societies and the sole recipient of many scientific awards.

Cell Biology, Ways to control cancer.

will be updated soon..

Scientific and educational activities in the fields of pharmaceutical chemistry and drug analysis. Research interests are in the areas of micellization and thermodynamic study of selected drugs from the groups of local anaesthetics and beta-adrenolytics.

Dean of the medical and pharmacy school at Shaqra university, Chair of the International Collaboration Committee for Health Science College and Leader for the entrepreneurship and innovation initiative to develop the society in the Arab world

Pharmaceutics

Abolfazl Akbarzadeh was born in Ahar, Iran in 1973. He has done his Ph.D in Medicinal Chemistry from Tabriz University of Medical Sciences in 2012. Presently he is an Associate Professor of Medicinal Chemistry(Nanobiomedicine)in Tabriz University of Medical Sciences, Tabriz, Iran.

Preparation and In-vitro Evaluation of Doxorubicin-Loaded Fe3O4 Magnetic Nanoparticles Modified with Biocompatible Copolymers in Lung Cancer Cells. Preparation of Polymeric Micro and Nanoparticles Containing Protein- Peptide and Anti Cancer Drugs.